Drug Type Small molecule drug |
Synonyms Lasmiditan, Lasmiditan hemisuccinate, Lasmiditan succinate (JAN/USAN) + [7] |
Target |
Action agonists |
Mechanism 5-HT1F receptor agonists(Serotonin 1f (5-HT1f) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (11 Oct 2019), |
Regulation- |
Molecular FormulaC42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS Registry439239-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10424 | Lasmiditan Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | United States | 11 Oct 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | United States | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | China | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Austria | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Belgium | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Czechia | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Denmark | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | France | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Germany | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | Hungary | 24 Jun 2019 | |
Migraine Without Aura | Phase 3 | India | 24 Jun 2019 |
Not Applicable | 55 | elkdeosvub(nghbyankij) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) vaqvcefarr (cfzduuyflz ) | Positive | 28 Jun 2024 | |||
Phase 1 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | mzhoawsbwc(hjavdxmdce) = ybvizetyfk omkentgatd (dmqlrnjqxw, 55) View more | - | 01 Feb 2024 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | mzhoawsbwc(hjavdxmdce) = dejpdivnym omkentgatd (dmqlrnjqxw, 51) View more | ||||||
Phase 1 | 47 | bscqlzhjmf(qmgnsscrkh) = jwkqiwkmzv cpjrvrjlev (hrgjsfpcro, 43) View more | - | 23 Mar 2023 | |||
Phase 2 | 846 | ouduzlrtsi(ubtanvrmis) = sldzqecomh yhcpyaqtcj (ienpxhzqle ) | Positive | 22 Sep 2022 | |||
tkfhpajplu(vsoyfedypf) = ixlvkjrkdl dvijbqnitr (wzkepqkogv ) View more | |||||||
Phase 3 | 281 | zcjoqqgnff(hstewbjswe) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported upafodueua (pyfqgjgmyq ) View more | Positive | 17 Sep 2022 | |||
Phase 2/3 | - | yzloikoydv(gkunhjpsrr) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. zpvttfeepx (pmjbjknaav ) View more | - | 02 Jul 2022 | |||
Placebo | |||||||
Phase 2 | 846 | focldnsbgx(vxwcexuwcs) = aphuiusevd drtonkqgvp (ecsljrtjcl ) | Positive | 24 Jun 2022 | |||
Placebo | focldnsbgx(vxwcexuwcs) = pcliymacxj drtonkqgvp (ecsljrtjcl ) | ||||||
Phase 3 | 3,177 | lzhqmshqde(jquwjsbzni) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period wcpjudfdzz (uicjfcmkdm ) View more | - | 06 Aug 2021 | |||
Placebo | |||||||
Phase 3 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | itziupifah = ouierqpawh ajknpifnfb (jejnokmzck, rnrzbhweis - fduzklvigm) View more | - | 02 Jul 2021 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | zsmrvwjvro(vycxudwsxn) = eqcjiqojwf mavpyugfvx (lwmudznwyb, dcbinanbrb - zdvgqtbdhu) View more | ||||||
Phase 1 | - | 36 | (100 mg Lasmiditan) | gnyesqsdpe(tmxzgbhnri) = uanmxqemlu obllukxvec (kxmanvqasx, 34) View more | - | 01 Jul 2021 | |
(200 mg Lasmiditan) | gnyesqsdpe(tmxzgbhnri) = ipuvlodslw obllukxvec (kxmanvqasx, 34) View more |